All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Eprenetapopt with azacytidine did not significantly improve CR rates in TP53-mutated MDS

Jan 11, 2021

Eprenetapopt (APR-246) is a p53 reactivator being investigated in several TP53-mutated hematologic malignancies. It has received Breakthrough Therapy, orphan drug, and Fast Track designations from the U.S Food and Drug Administration for TP53-mutated myelodysplastic syndromes (MDS).

The phase III trial NCT03745716 explores the combination of eprenetapopt with azacytidine versus azacytidine alone for untreated patients with at least one TP53 mutation, which is not benign or likely benign. On December 28, 2020, the trial sponsor announced that the trial had not met its primary endpoint: the complete response (CR) rates in the combination arm were superior but not statistically significant.

At data cut-off (N = 154), 33.3% (95% CI, 23.1%–44.9%) of patients receiving eprenetapopt with azacytidine achieved a CR, while in control arm the CR rate was 22.4% (95% CI, 13.6%–33.4%, p = 0.13). However, the press release states that with longer follow-up, secondary endpoints such as overall response rate and duration of response might favor the combination arm.

The safety profile of eprenetapopt plus azacytidine is consistent to date with previously reported single-arm phase II studies, like the GFM-APR246 trial (NCT03588078), presented at the 25th Congress of the European Hematology Association (EHA) by Thomas Cluzeau. Watch below a summary of their results.

Is azacitidine + APR-246 safe and effective in TP53 mutated MDS and AML?

Eprenetapopt showed promising activity as post-transplantation maintenance in MDS and AML and is also in clinical development for untreated and relapsed TP53-mutated AML.

  1. Aprea Therapeutics. Aprea Therapeutics announces results of primary endpoint from phase 3 trial of eprenetapopt in TP53 mutant myelodysplastic syndromes (MDS). Published Dec 28, 2020. Accessed Jan 6, 2021.